Identification | Back Directory | [Name]
Atorvastatin lactone | [CAS]
125995-03-1 | [Synonyms]
ATORVASTATIN LACTONE Atorvastatin d-Lactone Atorvastatin Impurity H (RS) Atorvastatin Lactone Atorvastatin EP IMpurity H Atorvastatin EPIMp H (USP RCH) Atorvastatin Calcium Impurity D Diepoxide Atorvastatin Lactone Diepoxide (4R,6R)-6-{2-[2-(4-Fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)pyrrol-1-yl]ethyl}-4-hydroxytetrahydro-2H-pyran-2-one 1-[2-[[(2R)-Tetrahydro-4β-hydroxy-6-oxo-2H-pyran]-2α-yl]ethyl]-5-(4-fluorophenyl)-2-isopropyl-4,N-diphenyl-1H-pyrrole-3-carboxamide (3R,5R)-7-[2-(4-Fluorophenyl)-5-isopropyl-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-yl]-3,5-dihydroxyheptanoic acid 1,5-lactone 5-(4-Fluorophenyl)-2-(1-methylethyl)-N,4-diphenyl-1-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1H-pyrrole-3-carboxamide Atorvastatin Related Compound H (20 mg) (5-(4-Fluorophenyl)-1-{2-[(2R, 4R)-4-hydroxy-6-oxotetrahydro-2H-pyran-2-yl]ethyl}-2-isopropyl-N,4-diphenyl-1H-pyrrole-3-carboxamide) | [Molecular Formula]
C33H33FN2O4 | [MDL Number]
MFCD00899262 | [MOL File]
125995-03-1.mol | [Molecular Weight]
540.63 |
Chemical Properties | Back Directory | [Appearance]
Slightly Yellow Solid | [Melting point ]
103-106°C | [alpha ]
D +26.05° (c = 1 in chloroform) | [Boiling point ]
674.8±55.0 °C(Predicted) | [density ]
1.24±0.1 g/cm3(Predicted) | [storage temp. ]
-20°C Freezer, Under Inert Atmosphere | [solubility ]
Chloroform (Slightly), DMSO (Slightly), Methanol (Slightly) | [form ]
Solid | [pka]
13.39±0.40(Predicted) | [color ]
White to Light Yellow | [Optical Rotation]
Consistent with structure | [Merck ]
14,864 |
Hazard Information | Back Directory | [Chemical Properties]
Slightly Yellow Solid | [Uses]
Atorvastatin intermediate as inhibitor of MAP kinase and/or HMG-CoA reductase for the treatment of inflammation | [Synthesis]
Calcium salt of (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl]-3,5-dihydroxyheptanoic acid (500 mg, 0.413 mmol) was used as a raw material, which was suspended in water (8 mL), EtOAc (4 mL) was added, and the mixture was cooled in an ice bath (4°C). An aqueous 0.2 M HCl solution (4.55 mL, 0.910 mmol) was added slowly and dropwise under vigorous stirring until a clarified solution was formed. The reaction mixture was gradually warmed to room temperature, followed by separation of the organic and aqueous layers. The aqueous layer was extracted with EtOAc (3 x 5 mL), the combined organic layers were washed with brine (5 mL), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The resulting foam (469 mg) was dissolved in toluene (20 mL) and the mixture was heated to 0°C and refluxed for 2.5 h under a Dean-Stark apparatus. Upon completion of the reaction, the mixture was cooled to room temperature and concentrated under reduced pressure. Purification by fast column chromatography (eluent: heptane/EtOAc, gradient from 1:3 to 1:5) afforded the target product 5-(4-fluorophenyl)-2-(1-methylethyl)-N,4-diphenyl-1-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1H-pyrrole-3-carboxamide (394 mg. (white foamy substance). NMR hydrogen spectrum (400 MHz, CDCl3) δ 7.24-7.10 (m, 9H), 7.09-6.96 (m, 5H), 6.92-6.82 (br s, 1H), 4.57-4.47 (m, 1H), 4.34-4.27 (m, 1H), 4.27-4.16 (m, 1H), 4.09-3.97 (m , 1H), 3.62-3.47 (m, 1H), 2.66 (ABdd, J = 17.7, 4.8 Hz, 1H), 2.55 (ABddd, J = 17.7, 3.4, 1.5 Hz, 1H), 2.11 (d, J = 2.9 Hz, 1H), 1.95-1.82 (m, 1H), 1.81-1.67 (m, 2H) , 1.63-1.57 (m, 1H), 1.56-1.45 (m, 6H). | [References]
[1] Patent: WO2017/137469, 2017, A1. Location in patent: Page/Page column 62 [2] Patent: CN105085497, 2017, B. Location in patent: Paragraph 0115; 0116; 0117 |
|
|